Shots:

• The P-III BouNDLess study involves assessing of continuous carbidopa/levodopa (ND0612- SC) infusion vs immediate-release carbidopa/levodopa (CD/LD- PO) in 300 patients with PD experiencing motor fluctuations- evaluating its safety- efficacy and tolerability
• Mitsubishi’s subsidiary NeuroDerm is leading the P-III study with primary objective to determine the effect of ND0612 on daily "GOOD ON" time as measured by a self-reported patient diary assessing motor function
• ND0612 is a liquid formulation of carbidopa and levodopa administered subcutaneously for PD patients and has also shown safe and well tolerated results in P-I and P-II studies. Additionally- NeuroDerm plans to file its NDA to the UD FDA

Click here to read full press release/ article | Ref: Mitsubishi Tanabe | Image: Bioworld